Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer.

ABSTRACT: This research found that the clinical outcomes (PFS, ORR, OS) of the non-platinum-based doublet regimen (docetaxel capecitabine combination) were similar to those of the platinum-based (oxaliplatin capecitabine combination) when used as first line therapy for MGC patients.

Background

Docetaxel, platinum and fluorouracil are the three most important drugs in the treatment of MGC. This study was to compare clinical outcomes of the docetaxel capecitabine combination and the oxaliplatin capecitabine combination as first-line therapy in MGC patients.

Methods

In this phase II trial, MGC patients were randomly assigned and treated with either TX (capecitabine 1000 mg/m²/twice daily/1-14 days and docetaxel 60/75 mg/m² on the 1st day) (because of toxicity, the do

SUBMITTER: Zhao XY 

PROVIDER: S-EPMC9643736 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature